Yes, a patient can have both mixed connective tissue disease (MCTD) and rheumatoid arthritis (RA) simultaneously.
Overlap between MCTD and RA is well-recognized in clinical practice, with MCTD itself being defined as an overlap syndrome that can include RA-like features, and true concurrent RA can coexist with MCTD. 1
Understanding the Overlap
MCTD is fundamentally an overlap syndrome characterized by features of multiple connective tissue diseases—including systemic lupus erythematosus, systemic sclerosis, polymyositis, and notably rheumatoid arthritis—in the presence of anti-U1RNP antibodies 2, 3. This creates two distinct clinical scenarios:
Scenario 1: RA-like Features as Part of MCTD
- Arthritis is a dominant feature in MCTD, occurring as a significant initial manifestation in approximately 89% of patients 4
- Up to 35% develop RA-like hand deformities and 47% develop contractures or persistent loss of joint motion 4
- Erosive arthritis occurs in 30% of MCTD patients, with radiographic abnormalities including erosions and cysts 4, 5
- Approximately 60% of MCTD patients may have deforming arthritis 6
Scenario 2: True Concurrent RA and MCTD
- 3% of systemic sclerosis cases overlap with RA, and similar overlaps occur with MCTD 7
- Concurrent autoimmune diseases are documented in 14-44% of autoimmune hepatitis cases, including both RA and MCTD 1
- Case reports document patients with confirmed MCTD who are also anti-CCP antibody positive (specific for RA), demonstrating true coexistence 2
Diagnostic Approach
When evaluating for concurrent MCTD and RA:
Serologic Testing:
- Anti-U1RNP antibodies (defining feature of MCTD) 3, 8
- Anti-CCP antibodies and rheumatoid factor (specific for RA) 7, 2
- Both can be positive simultaneously 2
Clinical Assessment:
- Look for core MCTD manifestations: edema of hands, synovitis, myositis, Raynaud's phenomenon, and acrosclerosis 8
- Assess for RA-specific features: symmetric polyarthritis, morning stiffness >1 hour, rheumatoid nodules
- Determine if deformities are reducible (more typical of MCTD/Jaccoud's arthropathy) or fixed (more typical of RA) 6
Radiographic Evaluation:
- Erosive changes can occur in both conditions 4, 5
- MCTD radiographs may show features of scleroderma, SLE, or RA, reflecting clinical diversity 5
- Fine-detail hand radiographs can reveal osteopenia, soft-tissue swelling, erosions, joint-space narrowing, and subluxations 5
Treatment Implications
The 2023 ACR/CHEST guidelines explicitly address treatment for both conditions when interstitial lung disease is present, listing both MCTD and RA separately with similar treatment algorithms, acknowledging they can coexist 9:
For ILD in either condition:
- First-line: Mycophenolate (preferred), with rituximab, azathioprine, or tocilizumab as alternatives 9
- Short-term glucocorticoids (≤3 months) for MCTD, with caution in those with scleroderma phenotype due to renal crisis risk 9
For RA management specifically:
- MTX remains first-line for active RA 10
- Treat-to-target approach aiming for remission or low disease activity 10
Critical Clinical Pitfalls
Don't dismiss erosive arthritis as excluding MCTD—30% of MCTD patients have erosive disease 4
Initial misdiagnosis is common—47% of MCTD patients presenting with arthritis initially receive an RA diagnosis, and 21% even receive gold therapy 4
Antibody profiles can evolve—patients may be anti-Jo-1 positive initially and later become anti-CCP positive as the disease declares itself 2
Pulmonary involvement is common in both—screen aggressively for interstitial lung disease, which affects both conditions and requires similar immunosuppressive management 9
MCTD with scleroderma phenotype requires special caution with glucocorticoids due to increased renal crisis risk 9
The coexistence requires recognition of both disease processes to optimize treatment, as each may require specific therapeutic considerations while sharing common immunosuppressive strategies.